🇸🇬·1d agoRegulatory
23 July 20263 Consumers, Including a 12-Year-Old, Experienced Serious Adverse Effects After Taking Products with Banned or Potent Medicinal IngredientsAudiencesConsumerHealthcare professionalIndustry memberProduct typeChinese Proprietary MedicinesHealth supplementsPress Releases
Publisher
H
HSA (Singapore)
Singapore
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- HSA (Singapore)
- Region
- Singapore
- Scope
- Regulatory
- Published
- July 23, 2026
- Language
- EN
Topics
regulatorsingapore
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on hsa.gov.sg
Leave the platform to read the original full article on the publisher site.
Source: HSA (Singapore)
Scope: Regulatory
Related coverage
More related coverage
Zambia Medicines Regulatory Authority (ZAMRA)/7h ago
GUIDELINES ON APPLICATION FOR GRANT OF MARKETING AUTHORISATION OF NON IVDS
Zambia Medicines Regulatory Authority
Zambia Medicines Regulatory Authority (ZAMRA)/7h ago
Guidelines of Traceability of Medicines
Download Here
Zambia Medicines Regulatory Authority (ZAMRA)/7h ago
Guidelines on Recall of Medicines and Allied Substance
Download Here
Zambia Medicines Regulatory Authority (ZAMRA)/7h ago
Template for comments on Guidelines on Identification and Labelling of Medicines and Allied Substances and Master Data Sharing
Download Here